BAD
INDIA
Trump’s 200% generic tariff threat would imperil Americans: Indian pharma
Effective August 1, 2026, all generic drugs being brought into the United States will continue to have a tariff of zero per cent for a two-year period of time, after which the tariff will be raised to 100% for a one-year period of time, and
Pulse Bharat · Why it matters
Read the original at The Hindu · Business ↗
Indian pharmaceutical companies face significant financial risk from potential US tariffs on generic drug imports, impacting affordable medicine access.
Also reported by 4 other newsrooms
Economic TimesIndian pharma shrugs off Trump's tariff threatTOI BusinessTrump's 200% tariff plan may be a bitter pill for US consumers; Dr Reddy's warns of costlier medicinesଧରିତ୍ରୀଡୋନାଲ୍ଡ ଟ୍ରମ୍ପଙ୍କ ବଡ଼ ଘୋଷଣା, ଜେନେରିକ୍ ଔଷଧ ଉପରେ ଲାଗିବ ଏତିକି % ଶୁଳ୍କMint · CompaniesTrump threatens 200% tariffs on generic drugs in 2028, wants manufacturing to move to US